Tyrosine kinase receptor (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are the first “tumor agnostic” drugs approved for pan‐cancer use. The gene discussed is TPM3; the disease is neoplasm.